Iovance Biotherapeutics (IOVA) Retained Earnings (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Retained Earnings of $3.6 billion for Q1 2026, up 9.24% year-over-year from $3.3 billion in Q1 2025, and up 3.07% quarter-over-quarter from $3.5 billion in Q4 2025.
Iovance Biotherapeutics (IOVA) Retained Earnings (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Retained Earnings for 17 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 9.24% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 9.24% YoY), while the FY2025 annual figure was $3.5 billion, up 11.68% from the prior year.
- Retained Earnings climbed to $3.6 billion in Q1 2026 per IOVA's latest filing, from $3.5 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $3.6 billion in Q1 2026 and bottomed at -$1.7 billion in Q1 2023.
- Historically, Retained Earnings has averaged $1.5 billion across 5 years, with a median of $2.6 billion in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 182.59% — and 2025, when it jumped 2812201.72%.
- Iovance Biotherapeutics' Retained Earnings stood at -$902000.0 in 2022, then surged by 287732.82% to $2.6 billion in 2023, then climbed by 19.33% to $3.1 billion in 2024, then advanced by 11.68% to $3.5 billion in 2025, then climbed by 3.07% to $3.6 billion in 2026.
- Business Quant data shows IOVA's Retained Earnings at $3.6 billion in Q1 2026, $3.5 billion in Q4 2025, and $3.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 3.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Bn |
| Mar 31, 2026 | 3.56 Bn |
| Dec 31, 2025 | 3.46 Bn |
| Sep 30, 2025 | 3.39 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Mar 31, 2025 | 3.26 Bn |
| Dec 31, 2024 | 3.10 Bn |
| Mar 31, 2024 | 116,000.00 |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.58 Bn |
| Jun 30, 2023 | 2.36 Bn |
| Mar 31, 2023 | -1.68 Bn |
| Dec 31, 2022 | -902,000.00 |
| Sep 30, 2022 | -1.46 Bn |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | -1.26 Bn |
| Dec 31, 2021 | -1.17 Bn |
| Sep 30, 2021 | 1.77 Bn |
| Jun 30, 2021 | 1.73 Bn |
| Mar 31, 2021 | -905.64 Mn |